Loading
AMEXHealthcareBiotechnology
Latest quote
$3.745
−$0.115 · -2.98%
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Regular session
$3.745
−$0.115 · -2.98%
Regular session · ET · Market data may be delayed.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Day range
Current $3.745
52-week range
Current $3.745
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
17
Overpriced
Sentiment
42
Mixed
Risk
74
High Risk
Momentum
33
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Day range
Current $3.745
52-week range
Current $3.745
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.9M USD | 5.17M USD | 4.53M USD | 5.51M USD | 4.47M USD |
| Cost of goods sold | 1.53M USD | 34.43M USD | 972K USD | 35.02M USD | 20.02M USD |
| Gross profit | 3.37M USD | −29.25M USD | 3.56M USD | −29.51M USD | −15.54M USD |
| Research and development | 23.72M USD | 34.43M USD | 33.77M USD | 35.02M USD | 20.02M USD |
| Selling, general, and administrative | 12.41M USD | 13.18M USD | 10.68M USD | 7.44M USD | 8.28M USD |
| Operating expenses | 34.6M USD | 13.18M USD | 44.45M USD | 7.44M USD | 8.28M USD |
| Interest income | 388K USD | 697K USD | 179K USD | 29K USD | 5K USD |
| Interest expense | 16.59M USD | 10.74M USD | 2.63M USD | 29K USD | 64K USD |
| Depreciation and amortization | 1.53M USD | 1.33M USD | 972K USD | 892K USD | 1.17M USD |
| Operating income | −31.22M USD | −42.44M USD | −40.89M USD | −36.95M USD | −23.82M USD |
| Net income | −173.8M USD | −18.92M USD | −69.05M USD | −36.92M USD | −23.16M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$15.00
300.53% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 10, 2019 | 1:14 | — | — |
Stock split | Apr 25, 2017 | 1:10 | — | — |
Stock split | Aug 7, 2015 | 1:50 | — | — |
Stock split | May 11, 2006 | 1:10 | — | — |
Effective May 10, 2019
1:14
Effective Apr 25, 2017
1:10
Effective Aug 7, 2015
1:50
Effective May 11, 2006
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.93M0.00%2.3T USD0.03%$381.97+0.63%
iShares Russell 2000 ETFIWM777.51K0.00%77.7B USD0.19%$279.34+0.64%
Vanguard Extended Market ETFVXF693.56K0.00%95.4B USD0.05%$235.19+0.88%
iShares Russell 2000 Growth ETFIWO428.24K0.00%14.04B USD0.24%$357.37+1.10%
Vanguard Russell 2000 ETFVTWO373.48K0.00%18B USD0.06%$112.82+0.64%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM160K0.13%116.54M USD0.73%$15.94+0.25%
iShares Micro-Cap ETFIWC145.35K0.01%1.32B USD0.60%$183.23+0.24%
Vanguard Russell 2000 Growth ETFVTWG70.93K0.00%1.7B USD0.06%$260.77+1.02%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
